Pirenoxine

Pirenoxine

Clinical data
Trade names	Catalin
ATCvet code	QS01XA91 (WHO)
Identifiers
IUPAC name 1,5-Dioxo-4H-pyrido[3,2-a]phenoxazine-3-carboxylic acid
CAS Number	1043-21-6
PubChem (CID)	4846
ChemSpider	4846
UNII	27L0EP6IZK
ECHA InfoCard	100.012.612
Chemical and physical data
Formula	C16H8N2O5
Molar mass	308.24512 g/mol
3D model (Jmol)	Interactive image
SMILES C1=CC=C2C(=C1)N=C3C(=CC(=O)C4=C3C(=O)C=C(N4)C(=O)O)O2
InChI InChI=1S/C16H8N2O5/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12/h1-6H,(H,18,19)(H,21,22) Key:OKPNYGAWTYOBFZ-UHFFFAOYSA-N

Pirenoxine (abbreviated PRX, trade name Catalin) is a medication used in the possible treatment and prevention of cataracts. A report in the journal of Inorganic Chemistry showed that in liquid solutions pirenoxine could cause decreased cloudiness of a crystallin solution produced to mimic the environment of the eye. Pirenoxine interacts with selenite or calcium ions that have been proven as factors leading to the formation of lens cataract.^[1]

Pirenoxine reduces the cloudiness of the lens solution containing calcium by 38% and reduced the cloudiness of the selenite solution by 11%.

References

1. Liao, J. H.; Chen, C. S.; Hu, C. C.; Chen, W. T.; Wang, S. P.; Lin, I. L.; Huang, Y. H.; Tsai, M. H.; Wu, T. H.; Huang, F. Y.; Wu, S. H. (2011). "Ditopic Complexation of Selenite Anions or Calcium Cations by Pirenoxine: An Implication for Anti-Cataractogenesis". Inorganic Chemistry. 50 (1): 365–377. doi:10.1021/ic102151p. PMID 21138325.